$900-Million Biopharmaceutical Park Planned for Shenzhen
ePT--the Electronic Newsletter of Pharmaceutical Technology
The Shenzhen government is planning to build a new national biopharmaceutical park in the Shenzhen Grand Industrial Zone.
The city government in Shenzhen in southern China's Guangdong province is planning to build a 2.92-mile2 national biopharmaceutical park in the Shenzhen Grand Industrial Zone.
The center will be designed for biopharmaceutical research and development and will house businesses in the biomedical engineering, marine biotechnology, biopharmaceuticals, modern Traditional Chinese Medicines, and chemical drugs industries.
The RMB 7.2-billion (USD 900-million) project will be funded by government and nongovernmental organizations and is subject to approval by China's National Development and Reform Commission (NDRC). The base is expected to have annual revenues of RMB 100 billion (USD 12.5 million).
The NDRC also has approved two other biopharmaceutical bases in Changchun (Jilin province) and Shijiazhuang (Hebei province).
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
